Hyman DM, Willis T, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol 35, 2017 (suppl; abstr LBA2501).
One-stop Breath Analyser: sneller duidelijkheid, minder belastend voor patiënt
okt 2025 | Astma, Longoncologie